[Evaluation Of Dosage Errors During Mass Treatment Campaigns Targeting Lymphatic Filariasis And Onchocerciasis In The Health Districts Of Bougouni And Kolondièba, Mali].

The aim of this study was to assess dosing errors when administering ivermectin (IVM) according to height, using a measuring cup with reference to the manufacturer's recommended dosage according to weight. For this purpose, a secondary analysis of the database of a community trial conducted in the health districts of Bougouni and Kolondièba was carried out. This made it possible to assess the proportions of participants who received underestimated doses, and to identify the factors associated with underestimation of IVM dose when using the toise. In all, 8.6% of participants (258/3011) received an underestimated dose. Of these, the most represented age group was the under-10s, with 63.18% (163/258), and the over-20s, with 25.19% (65/258). There was a significant correlation between missing dose quantities and height (r=17.1%, p=0.00593), as well as age (r=14.2%, p=0.02227). Participants under 10 years of age were 2.62 times (OR= 2.62; 95% CI: 1.58 - 4.43) more likely to be under-dosed than those aged 10 and over. Having a height of 120 cm or more made a participant 22.5 times (OR= 22.5; 95% CI: 13.5 - 38.4) more likely to be underdosed compared to those with a height ranging from 90 to 119 cm. These results suggest that it is crucial to make adequate adjustments to ensure a favorable response in CT participants in areas receiving MVI.